Why Analysts Are Abandoning Myriad Genetics Upside Hopes
24/7 Wall St. could not help but notice how many analysts on Wall Street have simply abandoned their old upside hopes for Myriad Genetics.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 201
Major Pharma Short Interest Slides
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
Short Sellers Run for Cover From Major Biotechs
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
What to Expect When Mylan Reports Earnings
Mylan is expected to release its second-quarter financial results after the markets close on Tuesday.
3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential
The analysts at Stifel have noted three biotech companies that not only have data that could prove to be huge, but also have stocks that have been absolutely hammered over the past year.
Is This Earnings Report the Start of the Valeant Turnaround?
Valeant Pharmaceuticals International appears to have a turnaround underway, after the company reported its second-quarter financial results before the markets opened on Tuesday.
Zika Threatens Florida’s $82 Billion Tourism Revenue
If the Zika virus should spread beyond its currently known location near Miami, it could threaten some of Florida's largest tourist attractions, like DisneyWorld and Universal Orlando.
Why Credit Suisse Sees Merck and Bristol-Myers Gap Widening Further
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
Why Allergan Earnings Aren’t Telling the Whole Story
Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.
Why Bristol-Myers Failure Is a Huge Win for Merck
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.
Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
Zika Threatens Florida’s $67 Billion Tourism Industry
In Miami, spraying for Zika is in full swing. However, infection rates continue to rise, and the virus has begun to spread among other states.
Theranos Death Watch (Update)
There have been several developments since 24/7 Wall St. posted its Theranos Death Watch Continues story.
Merrill Lynch Says the Time to Put Money Into Biotech Is Now
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
What Expect From Teva Earnings
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.